Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion type Assertion NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_head.
- NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion description "[We will not only detail new platforms that utilize leukocyte integrins as receptor targets for siRNAs delivery, but also show how one of these strategies has been utilized for in vivo drug target validation of a novel anti-inflammatory target, cyclin D1, for inflammatory bowel diseases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_provenance.
- NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion evidence source_evidence_literature NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_provenance.
- NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion SIO_000772 19221492 NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_provenance.
- NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion wasDerivedFrom befree-20140225 NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_provenance.
- NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_assertion wasGeneratedBy ECO_0000203 NP527822.RAc1-u-jLUpWW55qXWfD7KDSYSQ2yGUSPqwmGwLR33md8130_provenance.